Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Fovinaciclib (FCN-437c) in Advanced Solid Tumors
NCT03951116Phase 1Completed
- Sponsor
- Fochon Biosciences
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ongiciclib in solid tumor, non-small cell lung cancer (NSCLC) and breast cancer, sponsored by Fochon Biosciences. Primary endpoints: Occurrence of adverse events, Treatment-emergent adverse events and 1 more. Started Jun 2019; status: completed.
02
Drugs
ongiciclib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT03951116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951116.